and the Department of Pharmacology (P.J.P.), Royal College of Surgeons of England, Lincoln's Inn Fields, London. Correspondence to Professor Sir Magdi H. Yacoub, Thoracic and Cardiac Surgical Unit, Harefield Hospital, Harefield, Middlesex UB9, 6JH, UK. concentration-response curve. In contrast, LTC4 and LTD4 produced a response in IMAs from only 3 of 29 patients. LTC4 and LTD4 produced small contractions, of which the maximum responses were 3.28±1.92 mN (n=5) and 3.12±1.38 mN (n=5). LTE4 produced no responses in the IMA. Experiments in which the SV was pretreated with L-NG-monomethyl-L-arginine (L-NMMA; 10-4 mol/L) or indomethacin (105 mol/L) or was denuded of endothelium had no significant effect on the E.
Background Platelet aggregation with the release of their vasoactive mediators is an important factor contributing to the patency of coronary bypass grafts. However, the role of leukocyte-derived mediators on graft performance is unclear. Leukotrienes (LTs) are proinflammatory mediators released from a variety of leukocytes that possess both vasoactive and mitogenic properties. We have therefore compared the effects of the cysteinyl LTs (C4, D4, and E4) on the human saphenous vein (SV) and human internal mammary artery (IMA).
Methods and Results Human SVs from 43 patients (mean age, 58 years) and IMAs from 33 patients (mean age, 57 years) were obtained from individuals undergoing coronary artery bypass surgery for coronary artery disease. The samples were set up in organ baths to record changes in vessel wall tension. In undistended SVs the cysteinyl LTs elicited concentration-dependent contractions. The E. for LTE4 (4.23±1.0 mN; n=6) was significantly less than that observed with either LTC4 (25.7±4.01 mN; n=7; P<.001) or LTD4 (26.19±3.16 mN; n=7; P<.001). In addition, the LTD4 receptor antagonist ICI 198615 (30 nmol/L) significantly inhibited the LTD4 concentration-response curve but not the LTC4 responses. Furthermore, treatment of the SV with acivicin (0.05 mmol/L), a y-glutamyl transpeptidase inhibitor, caused a significant rightward displacement of the LTC4 Tl ahere is increasing evidence to suggest that the function and patency of coronary bypass grafts is influenced by their biological properties.1,2 The increased patency rates of the internal mammary artery (IMA) conduits compared with the saphenous vein (SV) are thought to be partly attributed to the greater ability of IMA endothelial cells to modulate vascular tone and increase thromboresistance through the release of endothelium-derived nitric oxide3 and prostacyclin. 4 The performance of coronary bypass grafts may also depend on the ability of smooth muscle cells to produce and/or respond to circulating or infiltrating inflammatory cells. This is particularly important in venous conduits that have poor antithrombotic properties,5 values for LTE4. Also, the IMA remained unresponsive to cysteinyl leukotrienes after treatment with L-NMMA or indomethacin or endothelium removal. In vitro autoradiography localized specific [3H]-LTC4 and [3HI-LTD4 binding sites (putative receptors) to the smooth muscle cells of both SV and IMA, with greater binding to the SV.
Conclusions Our data show that there is a preferential contraction to LTs in SV compared with IMA. This difference in smooth muscle cell reactivity to the cysteinyl LTs suggests that endogenous LT production from circulating or infiltrating leukocytes may be an important factor contributing to graft function. (Circulation. 1994; 90:515-524.) Key Words * leukotrienes * bypass grafts * endothelium * vascular reactivity which can result in an enhanced platelet and leukocyte vessel wall interaction during insertion of the graft.6'7 This cellular interaction can result in the release of a variety of mediators, including autocoids8'9 and growth factors,10 which could modulate vessel tone and accelerate smooth muscle cell growth and thus influence the evolution of disease in the conduit vein.
Leukotrienes (LTs) are proinflammatory mediators released from leukocytes by a variety of stimuli that possess both vasoactive"l '2 and mitogenic properties.13 '14 We have previously shown that the cysteinyl LTs C4 and D4 have a complex mode of action in vitro in the SV, including both vasodilator effects at low concentrations (picomoles) and vasoconstrictor effects at high concentrations (nanomoles), which were unaffected by endothelial removal. 15 We have also found raised levels of urinary LTE4 (a stable metabolite of the cysteinyl LTs) in patients after coronary artery bypass surgery, 16 indicating an increased production of cysteinyl LTs. LTE4 also possesses vasoactive properties17; therefore, we have compared the effects of LTE4 with those of LTB4, LTC4, and LTD4 on the SV and examined the effect of the competitive LTD4 receptor antag-516 Circulation Vol 90, No 1 July 1994 onist ICI 198615 on LT responses. In addition, we studied the effects of LTB4, LTC4, LTD4, and LTE4 on the IMA to compare the reactivity of both vessels to these inflammatory mediators and used in vitro receptor autoradiography to localize specific binding sites in these two vascular conduits.
Methods

In Vitro Organ Bath Experiments
Human undistended SVs from 43 patients (mean age, 58 years; range, 44 to 69 years old), and human IMAs from 33 patients (mean age, 57 years; range, 38 to 72 years old) were obtained during coronary artery bypass surgery. The blood vessels were immediately placed in a modified Tyrode's solution of the following composition (mmol/L concentration): NaCl 136.9, NaHCO3 11.9, KCl 2.7, NaH2PO4 0.4, MgCl2 2.5, CaCl2 2.5, glucose 11.1, and disodium EDTA 0.04. The blood vessels were then dissected free of connective tissue, cut into 4to 5-mm ring segments, and mounted between two L-shaped metal hooks suspended in 5-mL organ baths connected to a Grass FTO-3C force displacement transducer coupled to a Grass 79D polygraph to monitor and record changes in vessel wall tension. The baths were filled with 5 mL Tyrode's solution and aerated at 37°C with a gas mixture of 95% 02 and 5% CO2. Protocol SVs and IMAs were initially stretched to give a preload of 60 mN and 40 mN of force, respectively. These preloads have been shown to be optimal for maximal isometric contraction in response to 90 mmol/L KCI. The vessels were then allowed to relax and equilibrate for 60 minutes. When resting tension was stable, each segment was challenged twice with 90 mmol/L KCI to assess the contractile response of the tissue, the bathing solution being changed between doses when the KCl responses reached a plateau. After two KCI responses, the tissues were washed and allowed to equilibrate for 30 minutes. The rings were then studied in pairs, and doses of either LTB4, LTC4, LTD4, or LTE4 were added to each bath in a cumulative manner. In another group of tissues the effect of the thromboxane mimetic U46619 was compared. Only one cumulative concentration-response curve was established in each ring segment.
Effects of ICI 198615 on LTC4 and LTD4 Responses
Some tissues were incubated for 30 minutes with vehicle (30 nmol/L and 0.3 ,umol/L dimethylsulfoxide) or ICI 198615 (30 nmol/L and 0.3 ,mol/L) before producing concentrationresponse curves to each LT. In another group of tissues, segments of SV were incubated with ICI 198615 (30 nmol/L) in the presence or absence of acivicin (0.05 mmol/L), an irreversible y-glutamyl transpeptidase inhibitor18 that prevents the metabolism of LTC4 to LTD4. In other segments, LTC4 concentration-response curves were performed in the presence of acivicin (0.05 mmol/L) alone, whereas LTD4 concentrationresponse curves were performed in the presence or absence of L-cysteine (3 mmol/L) to block the metabolism of LTD4 to LTE4.
Endothelial Modulation
In another series of experiments quiescent vessels were preincubated with L-NG-monomethyl-L-arginine (L-NMMA; 100 ,umol/L) to inhibit the formation of endothelium-derived nitric oxide or with indomethacin (10 ,umol/L) to block the synthesis of cyclooxygenase products for 30 minutes before the addition of the LTs. In other experiments the endothelial cell layer of the vessels was removed by gently rubbing the intraluminal surface with forceps. Confirmation of endothelium removal was achieved by the lack of a relaxatory response to acetylcholine.
We have already established that LTC4 and LTD4 have dilator effects in the SV15; therefore, a separate series of experiments were performed to determine whether LTE4 had any dilator effects in the SV and whether LTC4, LTD4, and LTE4 have any vasodilator actions in the IMA. To induce a preconstriction in the vessel segments, norepinephrine (0.1 to 0.3 ,umol/L) was added to the Tyrode's solution bathing the tissue. Once a stable plateau had been reached, cumulative additions of LTs were made. As a positive control, relaxation to acetylcholine was performed.
In Vitro Autoradiography
Tritiated LT binding sites in SV and IMA were localized by in vitro autoradiography. SV and IMA were obtained from an additional nine patients undergoing coronary artery bypass surgery and immediately snap frozen before the experiments. Because of the greater supply of SV tissue, this vessel was used in the preliminary experiments (n=6) to determine the optimum incubation time (association experiments) and washout times (dissociation experiments) for the saturation experiments.
Saturation Experiments
Slide-mounted sections of both vessel types were initially preincubated in 50 mmol/L Tris HCI buffer, pH 7.4, for 15 minutes at 4°C to reduce levels of endogenous leukotrienes. Slides were then incubated in buffer containing 5 mmol/L CaCl2, 0.05 mmol/L acivicin, and 20 mmol/L L-cysteine in the presence of 0.01 to 3.0 nmol/L [3H]-LTC4 or [3H]-LTD4 (specific activity, 154 Ci/mmol; NEN Dupont) for 60 minutes at 4°C. The acivicin prevented the metabolism of LTC4 to LTD4 during incubation, and L-cysteine prevented the metabolism of LTD4 to LTE4. The degree of nonspecific binding was established by incubating alternate sections in the presence of 1 ,umol/L unlabeled LTC4 or LTD4 (Cascade Biochemicals Ltd). After incubation, sections were washed twice for 5 minutes (determined from the dissociation data), in buffer at 4°C, dipped in cold distilled water (4°C), and dried in a stream of cold air. Low-resolution autoradiography was performed by exposing incubated sections to Hyperfilm 3H (Amersham) for 5 weeks. The film was processed in undiluted D19 developer (Kodak) and fixed in IF23 fixer (Ilford, diluted 1 to 4 in distilled water), both for 5 minutes at 22°C. Low-resolution autoradiographs were examined and photographed on a Nikon macro system. Estimation of [3H]-LTC4 and [3H]-LTD4 binding was performed by wiping off tissue sections from the microscope slides with Nucwipes (National Diagnostic), which were then placed in Ultragold scintillant (4.5 mL) and counted for tritium for 2 minutes. Background counts were subtracted from all readings and specific binding, and then calculated by subtracting nonspecific binding from total binding. [3H]-LTC4 and [3H]-LTD4 binding sites were identified at a microscopic level (high-resolution autoradiography) by apposing sections to coverslips coated with emulsion19 (LM1, Amersham) and exposing for 6 weeks in lightproof boxes at 4°C. After exposure, the emulsion-covered coverslips were also processed in undiluted D19 developer (Kodak), briefly placed in stop solution (Ilford) for 15 seconds, and fixed in IF23 (Ilford, diluted 1 to 4 in distilled water), both for 5 minutes at 22°C. Tissue was then stained with Mayer's hematoxylin and eosin for histological examination. Autoradiographs and stained tissue were examined under dark-field and bright-field illumination on an Olympus Vanox microscope.
Drugs
The following drugs were used: LTB4, LTC4, LTD4, and LTE4 (Cascade); [3H1-LTC4 and [3H]-LTD4, emulsion (LM-1), and Hyperfilm 3H (Amersham); L-NMMA (a gift from Wellcome Laboratories); acivicin, L-cysteine, indomethacin, and Tris HCI (Sigma Chemical Company Ltd); and ICI 198615 (ICI Pharmaceuticals). Drug concentrations refer to final molarity within the organ bath solution. LTs were obtained as stock solutions dissolved in solvent (MeOH: H20: AcOH) and packed under argon. The stock solutions were divided into aliquots and stored under an atmosphere of nitrogen at -40°C. For each experiment, an aliquot was diluted with distilled water to an appropriate concentration and kept on ice. Indomethacin was dissolved in 100 mmol/L sodium carbonate and then further diluted in distilled water. L-NMMA was dissolved in distilled water, and ICI 198615 was dissolved in dimethylsulfoxide and then further diluted in distilled water. 
Results
Effect of Cysteinyl LTs on Resting Tone
The concentration-response curves for the different LTs are shown in which was significantly less than that observed with either LTC4 (25.7±4.01 mN; n=7; P<.001) or LTD4 (26.19±3.16 mN; n=7; P<.001) (Fig 1, upper panel) . The maximum responses of LTC4, LTD4, and LTE4 when compared as a percentage of the maximum response elicited by 90 mmol/L KCl were 80.58±14.19%, 76.40+10.04%, and 11.6±2.9%, respectively. The contractions induced by each LT were slow in onset, and duration of the maximum response was protracted. LTE4 had the longest duration of action, inducing contractions that were at least twice those caused by LTC4 and LTD4 (LTE4, 46.3±6.8 minutes versus LTC4 and LTD4, 14.8±2.0 minutes; P<.01). The chemotactic LT B4 (1 nmol/L to 0.1 ,mol/L) had no effect on vascular tone in the SV (n=4).
In contrast to their effects in the SV, neither LTC4 nor LTD4 produced efficacious contractions in the IMA (Fig 1, lower panel) . The IMA responded to LTC4 and LTD4 with small contractions; the Emax values were 3.28±1.92 mN to LTC4 in 3 of 5 and 3.12±1.38 mN to LTD4 in 3 of 5, which was equivalent to 20.77±10.59% and 17.54±9.78%, respectively, of the response produced by 90 mmol/L KCl. LTB4 (n=4) and LTE4 (n=6) produced no contractile responses in IMA at concentrations up to 0.1 ,imol/L. When the responsiveness of the SV and IMA was examined with the thromboxane mimetic U46619 (1 nmol/L to 0.3 ,umol/L), U46619 produced a similar maximum tension in both tissues: Emax, 147.5±11.5% for SV and 152±35.4% for IMA, and a lower ECs0 value: pD2, 8 
Influence of the Endothelium on LTE4
Responses in SV Results derived from experiments in which the SVs were pretreated with L-NMMA (100 ,umol/L) or indomethacin (10 ,umol/L) or denuded of their endothelium before establishing concentration-response curves to LTE4 are presented in Table 1 . The data obtained from paired preparations indicated that these treatments did not significantly alter the Ema. values of LTE4 in these tissues (n=6). In another series of experiments in which TABLF the SVs were preconstricted with norepinephrine (0.1 ,umol/L), LTE4 (1 pmol/L to 10 nmol/L) did not relax the preconstricted ring segments (0% change in norepinephrine-induced tone; n=3). Influence of the Endothelium on Cysteinyl LT Responses in IMA Similarly, control segments were unresponsive to LTC4 and LTD4 in the IMA, showing no increase in developed tension (0 mN) from the baseline. IMA segments treated with L-NMMA or indomethacin or denuded of their endothelium also remained unresponsive to LTC4 (0 mN; n=6) or LTD4 (0 mN; n=6) and did not unmask contractile responses to LTE4 (0 mN; n=6). The unresponsiveness of IMA segments to LTs was not caused by vessel wall damage because the vessels responded to 90 mmol/L KCl. Furthermore, the cysteinyl LTs were also unable to relax the IMA at concentrations ranging from 1 pmol/L to 10 nmol/L (0% change in norepinephrine-induced tone; n=6). The pKe values were calculated using the following formula: K6=[antagonist]/(dose ratio-1). These values were calculated only when there was a significant (P<.05) displacement of the agonist curves subsequent to the drug treatments. When the curves were not significantly (NS) shifted no pI values were calculated. formed with ICI 198615 (30 nmol/L) failed to inhibit LTC4-induced contractions (n=6); however, at the higher concentration ICI 198615 (0.3 ,umol/L) significantly antagonized the LTC4 concentration-response curve ( Table 2 ; n=6).
Effect of ICI 198615 on LT Responses in SV
The results derived from experiments in which SVs were pretreated with acivicin (0.05 mmol/L) before LTC4 concentration-response curves were established are presented in Fig 3. These data obtained from the paired preparations indicated that this treatment caused a significant displacement of the LTC4 concentration-response curve (n=6). The LTC4 pD2 values were 7.67±0.05 for the control group, and 7.45±0.09 for the acivicin-treated group (P<.05). In addition, ICI 198615 (30 nmol/L) in the presence of acivicin (0.05 mmol/L) failed to inhibit the LTC4 dose-response curve; the LTC4 pD2 values were not significantly different between the two groups (LTC4+acivicin, 7.45±0.09; LTC4+acivicin+ICI 198615, 7.55±0.09).
When SVs were pretreated with L-cysteine (3 mmol/L), the LTD4 pD2 values (7.89±0.10) were not significantly different from controls (7.78±0.07). The LTD4 E was 3 .0 nmol/L) to both the SV (Fig 4) and IMA ( Fig  5) . Estimation of binding data appeared to show differences in the degree of specific binding of [3H]-LTC4 ( Fig 6) and [3H]-LTD4 (Fig 7) . The IMA showed less specific [3H]-LTC4 (Fig 8) and [3H]-LTD4 binding (Fig 9) than the SV, although no statistical analysis was performed because of the low number of samples in each group. .s03 1.0 High-Resolution Autoradiography of SV and IMA High-resolution autoradiography showed [3H]-LTC4 and [3H]-LTD4 binding that was primarily localized to the tunica media, with less binding to the adventitia and no evidence of binding to the endothelium. 
Discussion
This article describes the comparative effect of the cysteinyl LTs in human SV and IMA. Our data show for the first time that there is a preferential contraction to LTs in the SV compared with the IMA and that this disparity in responsiveness was not caused by the influence of endothelium-derived relaxing factors opposing LT-induced contractions in the IMA. In addition, there was no hyperactivity to U46619 in the SV compared with the IMA.
The cysteinyl LT responses in the IMA were unaffected by L-NMMA or indomethacin treatment, suggesting that relaxing factors released from the endothelium were not masking LT-induced contractions. Previous studies have shown preferential endothelial modulation of responses to various vasoconstrictors 3.0 between the IMA and SV2u; however, it appears from our experiments that this mechanism does not account for the different responses of the IMA and SV to LTs, which is probably due to the specific LT-receptor profile of the smooth muscle cells in these vessels.
To examine further the mechanisms of the LT- smooth muscle cells because endothelial removal in the vessels did not affect LT contractions.15 Our present data support this, showing that tritiated LT binding was also localized primarily to the tunica media. shown that the presence of atherosclerosis can augment the response to LTs.22 It is possible that these three arteries may have had some degree of early atherosclerotic changes, although this was not evident on macroscopic examination. Several possibilities exist for interpretation of the binding data. Binding sites for LTs on enzymes or transport proteins rather than functionally important receptors might account for the specific binding observed.21,23 Alternatively, the binding sites may represent LT receptors that are not linked to vasomotion. For example, LTs are known to have both mitoge-nic13'14 and vascular permeability effects.24 Lastly, the difference in vascular reactivity between the SV and IMA may be caused by other reasons such as an altered receptor number or affinity or postreceptor alterations in signal transduction in vascular smooth muscle. Further studies are needed to identify the function of these LT binding sites to clarify the mechanism of the LTinduced vascular hyperreactivity in the SV. The actions of LTs are complex, and the pharmacological studies that attempt to characterize the cysteinyl LT receptors in several tissues are frequently compromised by secondary events such as mediator release25 or LT metabolism.26 Previous studies have shown that LTC4 in the absence of L-serine borate complex may be degraded to LTD4 by enzymatic activity of y-glutamyl transpeptidase.27 In this study, the sensitivity of the LTC4 concentration-response curves in the presence of acivicin were significantly shifted to the right, and the antagonist activities of ICI 198615 were lost. These results suggest that this enzyme rapidly metabolizes LTC4 so that the major contractile effect of LTC4 in the SV is caused by its conversion to LTD4. In addition, we were unable to show that L-cysteine affects LTD4 concentration-response curves, which is similar to previous findings.28
Our results suggest a heterogeneous population of LT receptors in the human SV, one which is ICI 198615sensitive and is specific for LTD4 and the other ICI 198615-insensitive, which appears to be specific for LTC4. This heterogeneity is further supported by the reported differences in pK4 values for LT responses and the apparent differences in triLiated LT binding characteristics in the SV.
These findings may have important consequences for graft function and patency. The IMA has a potent endogenous nitric oxide system that can protect against vasospasm and thrombus formation and thus prevent graft occlusion. In addition, the present findings suggest that IMA vascular smooth muscle cells have a reduced capacity to constrict to certain endogenous inflammatory mediators such as LTs, which may further aid protection against thrombus formation. In contrast, in SVs the endothelial-L-arginine pathway is much less active, and its effects are inhibited by concominantly released endothelium-derived constricting factors.5 Previous studies have shown the importance of plateletendothelial interactions in SV grafts with a decrease in the early occlusion rate with antiplatelet therapy.29 However, the contribution of leukocyte-endothelial interactions on graft performance is not clear. LTs are produced by activation of various white blood cells, including neutrophils,30 monocytes,31 and eosinophils.32 LTC4 and LTD4 are known to induce adhesion of polymorphonuclear leukocytes to human endothelial cells through the production of platelet-activating factor. 33 There is also evidence that LTs, in particular LTB4, enhance leukocyte adhesion to the endothelium, and inhibition of endogenous LT biosynthesis prevents postischemic leukocyte adhesion and tissue injury in an animal model. 34 The importance of leukocyte-endothelium interactions to graft function was highlighted by a recent report showing an increase in platelet and leukocvte adhesion and reduced short-term patency in pig arteriovenous bypass grafts. We have shown that SV vascular smooth muscle cells are reactive to LTC4 and LTD4 and are less reactive to LTE. LTE4 although less potent and efficacious than either parent molecule, retains some biological activity in the SV. Owing to its stability and sustained action, LTE4 may therefore persist in the circulation for a longer time than either LTC4 or LTD4. This feature of LTE4 may be important to graft function in light of the recent findings showing that LTE4 led to a selective recruitment of eosinophils and neutrophils in vivo.5 In the event of the generation of cysteinyl LTs in patients with arterialized SV grafts. marked contractions to LTC4 and LTD4. such as occur in the SV. could reduce local blood flow at sites where leukocytes are activated. In addition, LTC4 may potentiate the effects of cate-cholamines36 and thromboxane A,37 which could further increase contraction of SV, whereas LTE4 could act to recruit further leukocytes and thus favor thrombus formation. Indeed, the arterialized SV grafts remain responsive to LTC,3s indicating that LT responses are conserved after arterialization of the SV. LTs may be produced during cardiopulmonary bypass. because extracorporeal circulation of blood is known to activate leukocvtes.',9 To support this, we have recently shown that LT levels are raised in patients with coronarv artery disease and after coronary artery bypass surgery.'" Furthermore. leukocytes in vitro can produce concentrations of LTC4 in the range of 7 to 40 ng/106 leukocytest4' which is in the concentration range (EQ, value) for producing a biological effect in the SV.
Together, these findings suggest that activated white blood cells could produce sufficiently high local concentrations of LTs to induce contraction and therefore influence blood flow through the vein graft. In addition, it is possible that LT release from white blood cells may form the basis of an amplification mechanism to further leukocvte recruitment into SV grafts.
Thus, the preferential contraction of LTs on SVs compared with IMAs. together with the recent clinical evidence of an enhanced production of LTs,'" suggests that endogenous LT production may be an important factor contributing to graft function and that LT bio- 
